Overview

Bioequivalence of Amphotericin B Liposome for Injection

Status:
Completed
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the bioequivalence of two different amphotericin B liposome for injection after single IV infusion at the same dose in normal healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Treatments:
Amphotericin B
Liposomal amphotericin B